CSIMarket
 


Biospecifics Technologies Corp  (BSTC)
Other Ticker:  
 
 

BSTC's EPS from Cont. Operations Growth by Quarter and Year

Biospecifics Technologies's EPS from Cont. Operations results by quarter and year




BSTC EPS from Cont. Operations (in $) FY 2020 FY 2019 FY 2018 FY 2017
IV Quarter December - 1.00 0.92 0.30
III Quarter September 0.73 0.86 0.69 0.38
II Quarter June 0.02 0.88 0.60 0.47
I Quarter March 0.61 0.61 0.55 0.41
FY   1.36 3.35 2.76 1.56



BSTC EPS from Cont. Operations third quarter 2020 Y/Y Growth Comment
Biospecifics Technologies Corp reported decline in EPS from Cont. Operations in the third quarter 2020 by -15.12% to $ 0.73 , from the same quarter in 2019.
The contraction in the third quarter 2020 Biospecifics Technologies Corp's EPS from Cont. Operations compares unfavorably to the Company's average EPS from Cont. Operations rise of 38.6%.

Looking into third quarter 2020 results within Major Pharmaceutical Preparations industry 25 other companies have achieved higher EPS from Cont. Operations growth. While Biospecifics Technologies Corp' s EPS from Cont. Operations fall of -15.12% ranks overall at the positon no. 1336 in the third quarter 2020.




BSTC EPS from Cont. Operations ( Y/Y Growth %) 2020
2019 2018 2017
IV Quarter December - 8.7 % 206.67 % -30.23 %
III Quarter September -15.12 % 24.64 % 81.58 % 2.7 %
II Quarter June -97.73 % 46.67 % 27.66 % 17.5 %
I Quarter March 0 % 10.91 % 34.15 % 7.89 %
FY   - 21.38 % 76.92 % -1.27 %

Financial Statements
Biospecifics Technologies's third quarter 2020 EPS from Cont. Operations $ 0.73 BSTC's Income Statement
Biospecifics Technologies's third quarter 2019 EPS from Cont. Operations $ 0.86 Quarterly BSTC's Income Statement
New: More BSTC's historic EPS from Cont. Operations Growth >>


BSTC EPS from Cont. Operations (Quarter on Quarter Growth %)

2020
2019 2018 2017
IV Quarter December - 16.28 % 33.33 % -21.05 %
III Quarter September 3550 % -2.27 % 15 % -19.15 %
II Quarter June -96.72 % 44.26 % 9.09 % 14.63 %
I Quarter March -39 % -33.7 % 83.33 % -4.65 %
FY (Year on Year)   - 21.38 % 76.92 % -1.27 %




EPS from Cont. Operations third quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #26
Healthcare Sector #103
Overall #1336

EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
204.35 % 38.6 % -97.73 %
(Dec 31 2018)   (Jun 30 2020)
EPS from Cont. Operations third quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #26
Healthcare Sector #103
Overall #1336
EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
204.35 % 38.6 % -97.73 %
(Dec 31 2018)   (Jun 30 2020)

EPS from Cont. Operations by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Biospecifics Technologies's Q/Q EPS from Cont. Operations Growth


EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
3550 % 121.27 % -96.72 %
(Sep 30 2020)  


BSTC's III. Quarter Q/Q EPS from Cont. Operations Comment
Biospecifics Technologies Corp achieved in the III. Quarter 2020 above company average sequential EPS from Cont. Operations doubling of 3550%, to $ 0.73 , from $0.02 in the second quarter.
BSTC is undergoing a remarkable growth, with recording higher then average increase, and additionally increasing speed.

Within Major Pharmaceutical Preparations industry Biospecifics Technologies Corp achieved highest sequential EPS from Cont. Operations growth. While Biospecifics Technologies's EPS from Cont. Operations growth quarter on quarter, overall rank is 8.


EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #1
Healthcare Sector #1
Overall #8
EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #1
Healthcare Sector #1
Overall #8
EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
3550 % 121.27 % -96.72 %
(Sep 30 2020)  


BSTC's III. Quarter Q/Q EPS from Cont. Operations Comment
Biospecifics Technologies Corp achieved in the III. Quarter 2020 above company average sequential EPS from Cont. Operations doubling of 3550%, to $ 0.73 , from $0.02 in the second quarter.
Major Pharmaceutical Preparations company is undergoing a remarkable growth, not only reporting above average growth, and additionally increasing pace.

Within Major Pharmaceutical Preparations industry Biospecifics Technologies Corp achieved highest sequential EPS from Cont. Operations growth. While Biospecifics Technologies's EPS from Cont. Operations growth quarter on quarter, overall rank is 8.


Biospecifics Technologies's 12 Months EPS from Cont. Operations Growth Year on Year


EPS from Cont. Operations TTM Growth

12 Months Ending
(Sep 30 2020)
12 Months Ending
(Jun 30 2020)
12 Months Ending
(Mar 31 2020)
12 Months Ending
(Dec 31 2019)
12 Months Ending
(Sep 30 2019)
Cumulative EPS from Cont. Operations 12 Months Ending $ 2.36 $ 2.49 $ 3.35 $ 3.35 $ 3.27
Y / Y EPS from Cont. Operations Growth (TTM) -27.88 % -19.74 % 18.66 % 21.24 % 52.75 %
Year on Year EPS from Cont. Operations Growth Overall Ranking # 1203 # 948 # 427 # 259 # 434
Seqeuential EPS from Cont. Operations Change (TTM) -5.22 % -25.66 % 0 % 2.35 % 5.48 %
Seq. EPS from Cont. Operations Growth (TTM) Overall Ranking # 1277 # 1296 # 692 # 696 # 534




Cumulative EPS from Cont. Operations growth Comment
Biospecifics Technologies's cumulative 12 months EPS from Cont. Operations continue to drop, but on the faster rate at -27.88% year on year, at Sep 30 2020 compare to the -19.74% decrease at Jun 30 2020. If the Biospecifics Technologies's fiscal year would end at Sep 30 2020, annual EPS from Cont. Operations would be $2 .

In the Healthcare sector 92 other companies have achieved higher trailing twelve month EPS from Cont. Operations growth. While EPS from Cont. Operations growth total ranking has deteriorated compare to previous quarter from 948 to 1203.

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
32.38 %
5.28 %
-25.66 %
 

EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 33
Healthcare Sector # 93
Overall # 1203

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
99.12 %
32.38 %
-27.88 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 33
Sector # 106
S&P 500 # 1277
Cumulative EPS from Cont. Operations growth Comment
Biospecifics Technologies's cumulative 12 months EPS from Cont. Operations continue to drop, but on the faster rate at -27.88% year on year, at Sep 30 2020 compare to the -19.74% decrease at Jun 30 2020. If the Biospecifics Technologies's fiscal year would end at Sep 30 2020, annual EPS from Cont. Operations would be $2 .

In the Healthcare sector 92 other companies have achieved higher trailing twelve month EPS from Cont. Operations growth. While EPS from Cont. Operations growth total ranking has deteriorated compare to previous quarter from 948 to 1203.

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
32.38 %
5.28 %
-25.66 %
 


EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 33
Healthcare Sector # 93
Overall # 1203

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
99.12 %
32.38 %
-27.88 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 33
Sector # 106
S&P 500 # 1277




Other EPS from Cont. Operations Growth
Major Pharmaceutical Preparations Industry EPS from Cont. Operations Growth Trends and Statistics
Healthcare Sector EPS from Cont. Operations Growth Statistics
EPS from Cont. Operations Growth Trends for overall market
BSTC's EPS from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking EPS from Cont. Operations Growth
Lowest Ranking EPS from Cont. Operations Growth
EPS from Cont. Operations Growth for BSTC's Competitors
EPS from Cont. Operations Growth for Biospecifics Technologies's Suppliers
EPS from Cont. Operations Growth for BSTC's Customers

You may also want to know
BSTC's Annual Growth Rates BSTC's Profitability Ratios BSTC's Asset Turnover Ratio BSTC's Dividend Growth
BSTC's Roe BSTC's Valuation Ratios BSTC's Financial Strength Ratios BSTC's Dividend Payout Ratio
BSTC's Roa BSTC's Inventory Turnover Ratio BSTC's Growth Rates BSTC's Dividend Comparisons



Companies with similar EPS from Cont. Operations drop for the quarter ending Sep 30 2020 within Healthcare SectorY/Y Change %EPS from Cont. Operations for the quarter ending Sep 30 2020
Masimo Corp-2.17%$ -2.174 
Orgenesis Inc -2.27%$ -2.273 
Mylan N v -2.70%$ -2.703 
Baxter International Inc -2.78%$ -2.778 
Eli Lilly And Company-2.92%$ -2.920 
Conmed Corporation-4.00%$ -4.000 
U S Physical Therapy Inc-7.58%$ -7.576 
Tactile Systems Technology Inc -7.69%$ -7.692 
Icu Medical Inc-7.75%$ -7.752 
Emergent Biosolutions Inc -10.71%$ -10.714 
3m Company-10.91%$ -10.909 
Viemed Healthcare Inc -12.50%$ -12.500 
Bruker Corporation-12.50%$ -12.500 
Acadia Healthcare Company Inc -14.29%$ -14.286 
China Health Industries Holdings Inc -14.78%$ -14.783 
Biospecifics Technologies Corp-15.12%$ -15.116 
Heartbeam Inc -16.67%$ -16.667 
Becton Dickinson And Company-16.98%$ -16.981 
Corcept Therapeutics Inc-17.39%$ -17.391 
Utah Medical Products Inc-19.00%$ -19.000 
Encompass Health Corporation-21.21%$ -21.212 
Intuitive Surgical Inc -22.09%$ -22.093 
Carlisle Companies Incorporated-23.27%$ -23.265 
Illumina Inc -23.27%$ -23.270 
Atrion Corporation-23.40%$ -23.404 
Innoviva Inc -28.21%$ -28.205 
Zynex inc -33.33%$ -33.333 
National Healthcare Corp-33.86%$ -33.858 
Msa Safety Incorporated-33.94%$ -33.945 
Dentsply Sirona Inc -34.21%$ -34.211 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com